Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors (original) (raw)
MC Hung YK Lau (1999)ArticleTitleBasic science of HER-2/neu: a review_Semin Oncol_ 26 51–59Occurrence Handle1:CAS:528:DyaK1MXmt1Sisbk%3DOccurrence Handle10482194 CASPubMed Google Scholar
S Menard E Tagliabue M Campiglio SM Pupa (2000)ArticleTitleRole of HER2 gene overexpression in breast carcinoma_J Cell Physiol_ 182 150–162Occurrence Handle10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-EOccurrence Handle1:CAS:528:DC%2BD3cXjtVGqsA%3D%3DOccurrence Handle10623878 ArticleCASPubMed Google Scholar
LN Klapper MH Kirschbaum M Sela Y Yarden (2000)ArticleTitleBiochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors_Advances in Cancer Res_ 77 25–79Occurrence Handle1:CAS:528:DC%2BD3cXltl2ktw%3D%3D CAS Google Scholar
Y Yarden (2001)ArticleTitleBiology of HER2 and its importance in breast cancer_Oncology_ 61 1–13Occurrence Handle10.1159/000055396Occurrence Handle1:CAS:528:DC%2BD3MXovFWjsLw%3DOccurrence Handle11694782 ArticleCASPubMed Google Scholar
Y Yarden (2001)ArticleTitleThe EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities_Eur J Cancer_ 37 S3–S8Occurrence Handle10.1016/S0959-8049(01)00230-1Occurrence Handle1:CAS:528:DC%2BD3MXntlOku78%3DOccurrence Handle11597398 ArticleCASPubMed Google Scholar
Y Yarden MX Sliwkowski (2001)ArticleTitleUntangling the ErbB signalling network_Nat Rev Mol Cell Biol_ 2 127–137Occurrence Handle10.1038/35052073Occurrence Handle1:CAS:528:DC%2BD3MXivVWnt7k%3DOccurrence Handle11252954 ArticleCASPubMed Google Scholar
DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich_et al._ (1989)ArticleTitleStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancer_Science_ 244 707–712Occurrence Handle1:STN:280:BiaB2c3hsVA%3DOccurrence Handle2470152 CASPubMed Google Scholar
T Cooke J Reeves A Lanigan P Stanton (2001)ArticleTitleHER2 as a prognostic and predictive marker for breast cancer_Ann Oncol_ 12 S23–S28Occurrence Handle11521717 PubMed Google Scholar
RM Neve HA Lane NE Hynes (2001)ArticleTitleThe role of overexpressed HER2 in transformation_Ann Oncol_ 12 S9–S13Occurrence Handle11521729 PubMed Google Scholar
E Tzahar Y Yarden (1998)ArticleTitleThe ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands_Biochim Biophys Acta_ 1377 25–37 Google Scholar
WJ Slichenmyer WL Elliott DW Fry (2001)ArticleTitleCI-1033, a pan-erbB tyrosine kinase inhibitor_Semin Oncol_ 28 80–85Occurrence Handle1:CAS:528:DC%2BD3MXpt1Wgu7c%3DOccurrence Handle11706399 CASPubMed Google Scholar
MM Moasser A Basso SD Averbuch N Rosen (2001)ArticleTitleThe tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells_Cancer Res_ 61 7184–7188Occurrence Handle1:CAS:528:DC%2BD3MXnsVehtrY%3DOccurrence Handle11585753 CASPubMed Google Scholar
H Roh JA Pippin DW Green CB Boswell CT Hirose N Mokadam JA Drebin (2000)ArticleTitleHER2/neu antisense targeting of human breast carcinoma_Oncogene_ 19 6138–6143Occurrence Handle1:CAS:528:DC%2BD3MXhsFyht74%3DOccurrence Handle11156527 CASPubMed Google Scholar
AS Rait KF Pirollo V Rait JE Krygier L Xiang EH Chang (2001)ArticleTitleInhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer_Cancer Gene Ther_ 8 728–739Occurrence Handle1:CAS:528:DC%2BD3MXnvVejsbs%3DOccurrence Handle11687896 CASPubMed Google Scholar
T Suzuki B Anderegg T Ohkawa A Irie O Engebraaten M Halks-Miller PS Holm DT Curiel M Kashani-Sabet KJ Scanlon (2000)ArticleTitleAdenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells_Gene Therapy_ 7 241–248Occurrence Handle1:CAS:528:DC%2BD3cXhtlyjsrg%3DOccurrence Handle10694801 CASPubMed Google Scholar
F Czubayko SG Downing SS Hsieh DJ Goldstein PY Lu BC Trapnell A Wellstein (1997)ArticleTitleAdenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation_Gene Therapy_ 4 943–949Occurrence Handle1:CAS:528:DyaK2sXmtVSqurs%3DOccurrence Handle9349431 CASPubMed Google Scholar
GD Lewis I Figari B Fendly WL Wong P Carter C Gorman HM Shepard (1993)ArticleTitleDifferential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies_Cancer Immunol Immunother_ 37 255–263Occurrence Handle1:CAS:528:DyaK2cXhtlWrtrk%3DOccurrence Handle8102322 CASPubMed Google Scholar
BM Fendly M Winget RM Hudziak MT Lipari MA Napier A Ullrich (1990)ArticleTitleCharacterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product_Cancer Res_ 50 1550–1558Occurrence Handle1:CAS:528:DyaK3cXhslKltrw%3DOccurrence Handle1689212 CASPubMed Google Scholar
P Carter L Presta CM Gorman JB Ridgway D Henner WL Wong AM Rowland C Kotts ME Carver HM Shepard (1992)ArticleTitleHumanization of an anti-p185HER2 antibody for human cancer therapy_Proc Natl Acad Sci USA_ 89 4285–4289Occurrence Handle1:CAS:528:DyaK3sXitFSqtb0%3DOccurrence Handle1350088 CASPubMed Google Scholar
HA Lane I Beuvink AB Motoyama JM Daly RM Neve NE Hynes (2000)ArticleTitleErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency_Mol Cell Biol_ 20 3210–3223Occurrence Handle10.1128/MCB.20.9.3210-3223.2000Occurrence Handle1:CAS:528:DC%2BD3cXivFSrsrk%3DOccurrence Handle10757805 ArticleCASPubMed Google Scholar
J Baselga L Norton J Albanell YM Kim J Mendelsohn (1998)ArticleTitleRecombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.[erratum appears in Cancer Res 59: 2020, 1999]Cancer Res58 2825–2831Occurrence Handle1:CAS:528:DyaK1cXksFCqt7g%3DOccurrence Handle9661897 CASPubMed Google Scholar
FM Yakes W Chinratanalab CA Ritter W King S Seelig CL Arteaga (2002)ArticleTitleHerceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action_Cancer Res_ 62 4132–4141Occurrence Handle1:CAS:528:DC%2BD38XlsV2ltr0%3DOccurrence Handle12124352 CASPubMed Google Scholar
V Dieras P Beuzeboc V Laurence JY Pierga P Pouillart (2001)ArticleTitleInteraction between Herceptin and taxanes_Oncology_ 61 43–49Occurrence Handle11694787 PubMed Google Scholar
DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton (2001)ArticleTitleUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2_N Engl J of Med_ 344 783–792Occurrence Handle1:CAS:528:DC%2BD3MXisVGktrc%3D CAS Google Scholar
MD Pegram DJ Slamon (1999)ArticleTitleCombination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity_Semin Oncol_ 26 89–95Occurrence Handle1:CAS:528:DyaK1MXmt1Sitr8%3DOccurrence Handle10482199 CASPubMed Google Scholar
CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart (2001)ArticleTitleFirst-line Herceptin monotherapy in metastatic breast cancer_Oncol_ 61 37–42Occurrence Handle1:CAS:528:DC%2BD3MXovFWjsLg%3D CAS Google Scholar
C Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart (2001)ArticleTitleGenentech H0650 study investigators: First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: a preliminary report_Eur J Cancer_ 37 S25–S29Occurrence Handle1:CAS:528:DC%2BD3MXpsVeksA%3D%3DOccurrence Handle11167088 CASPubMed Google Scholar
J Baselga (2001)ArticleTitleHerceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials_Oncology_ 61 14–21Occurrence Handle1:CAS:528:DC%2BD3MXovFWjsL0%3DOccurrence Handle11694783 CASPubMed Google Scholar
MA Cobleigh CL Vogel D Tripathy NJ Robert S Scholl L Fehrenbacher JM Wolter V Paton S Shak G Lieberman DJ Slamon (1999)ArticleTitleMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease_J Clin Oncol_ 17 2639–2648Occurrence Handle1:CAS:528:DyaK1MXmtlWrurk%3DOccurrence Handle10561337 CASPubMed Google Scholar
W Eiermann (2001)ArticleTitleInternational Herceptin Study Group: Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data_Ann Oncol_ 12 S57–S62Occurrence Handle11521723 PubMed Google Scholar
RA Nunes LN Harris (2002)ArticleTitleThe HER2 extracellular domain as a prognostic and predictive factor in breast cancer_Clin Breast Cancer_ 3 125–135Occurrence Handle12123536Occurrence Handle10.3816/CBC.2002.n.017 ArticlePubMed Google Scholar
AS Clark K West S Streicher PA Dennis (2002)ArticleTitleConstitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells_Mol Cancer Ther_ 1 707–717Occurrence Handle1:CAS:528:DC%2BD38XlsFSmtLk%3DOccurrence Handle12479367 CASPubMed Google Scholar
SA Price-Schiavi S Jepson P Li M Arango PS Rudland L Yee KL Carraway (2002)ArticleTitleRat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance_Int J Cancer_ 99 783–791Occurrence Handle1:CAS:528:DC%2BD38XksVajs78%3DOccurrence Handle12115478 CASPubMed Google Scholar
Y Lu X Zi Y Zhao D Mascarenhas M Pollak (2001)ArticleTitleInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst93 1852–1857Occurrence Handle1:CAS:528:DC%2BD38XltVWluw%3D%3DOccurrence Handle11752009 CASPubMed Google Scholar
A FazioParticlede YE Chiew RL Sini PW Janes RL Sutherland (2000)ArticleTitleExpression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines_Int J Cancer_ 87 487–498Occurrence Handle10918187 PubMed Google Scholar
M Hidalgo EK Rowinsky (2000)ArticleTitleThe rapamycin-sensitive signal transduction pathway as a target for cancer therapy_Oncogene_ 19 6680–6686Occurrence Handle1:CAS:528:DC%2BD3MXhsF2rs7w%3DOccurrence Handle11426655 CASPubMed Google Scholar
K Yu L Toral-Barza C Discafani WG Zhang J Skotnicki P Frost JJ Gibbons (2001)ArticleTitlemTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer_Endocr Relat Cancer_ 8 249–258Occurrence Handle11566616 PubMed Google Scholar
AB Motoyama NE Hynes HA Lane (2002)ArticleTitleThe efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides_Cancer Res_ 62 3151–3158Occurrence Handle1:CAS:528:DC%2BD38XksVyqs70%3DOccurrence Handle12036928 CASPubMed Google Scholar
CJ Vlahos WF Matter KY Hui RF Brown (1994)ArticleTitleA specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)J of Biol Chem269 5241–5248Occurrence Handle1:CAS:528:DyaK2cXjtFGit78%3D CAS Google Scholar
FM Yakes W Chinratanalab CA Ritter W King S Seelig CL Arteaga (2002)ArticleTitleHerceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action_Cancer Res_ 62 4132–4141Occurrence Handle1:CAS:528:DC%2BD38XlsV2ltr0%3DOccurrence Handle12124352 CASPubMed Google Scholar
CL Arteaga TT Ramsey LK Shawver CA Guyer (1997)ArticleTitleUnliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site_J of Biol Chem_ 272 23247–2354Occurrence Handle1:CAS:528:DyaK2sXmt1Wisro%3D CAS Google Scholar
AE Lenferink D Busse WM Flanagan FM Yakes CL Arteaga (2001)ArticleTitleErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways_Cancer Res_ 61 6583–6591Occurrence Handle1:CAS:528:DC%2BD3MXmsF2jt74%3DOccurrence Handle11522658 CASPubMed Google Scholar
H Kurokawa AE Lenferink JF Simpson PI Pisacane MX Sliwkowski JT Forbes CL Arteaga (2000)ArticleTitleInhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells_Cancer Res_ 60 5887–5894Occurrence Handle1:CAS:528:DC%2BD3cXnvVSntLw%3DOccurrence Handle11059787 CASPubMed Google Scholar
DP Brazil J Park BA Hemmings (2002)ArticleTitlePKB binding proteins_Getting in on the Akt. Cell_ 111 293–303Occurrence Handle1:CAS:528:DC%2BD38XovVakurg%3D CAS Google Scholar
YG Kwon HB Huang F Desdouits JA Girault P Greengard AC Nairn (1997)ArticleTitleCharacterization of the interaction between DARPP-32 and protein phosphatase 1 (PP-1): DARPP-32 peptides antagonize the interaction of PP-1 with binding proteins_Proc Natl Acad Sci USA_ 94 3536–3541Occurrence Handle1:CAS:528:DyaK2sXis1amtr0%3DOccurrence Handle9108011 CASPubMed Google Scholar
W Xu X Yuan YJ Jung Y Yang A Basso N Rosen EJ Chung J Trepel L Neckers (2003)ArticleTitleThe heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells_Cancer Res_ 63 7777–7784Occurrence Handle1:CAS:528:DC%2BD3sXptFOltrw%3DOccurrence Handle14633703 CASPubMed Google Scholar
AC Gingras B Raught N Sonenberg (2001)ArticleTitleRegulation of translation initiation by FRAP/mTOR_Genes Dev_ 15 807–826Occurrence Handle1:CAS:528:DC%2BD3MXivVams7k%3DOccurrence Handle11297505 CASPubMed Google Scholar
AEG Lenferink JF Simpson LK Shawver RJ Coffey JT Forbes CL Arteaga (2000)ArticleTitleBlockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice_Proc Natl Acad Sci USA_ 97 9609–9614Occurrence Handle1:CAS:528:DC%2BD3cXmtVentr0%3DOccurrence Handle10931950 CASPubMed Google Scholar
T Kute CM Lack M Willingham B Bishwokama H Williams K Barrett T Mitchell JP Vaughn (2004)ArticleTitleDevelopment of Herceptin resistance in breast cancer cells_Cytometry_ 5 86–93 Google Scholar
DW Fry (2003)ArticleTitleMechanism of action of erbB tyrosine kinase inhibitors_Expt Cell Res_ 284 131–139Occurrence Handle1:CAS:528:DC%2BD3sXitVyltL8%3D CAS Google Scholar
DW Rusnak K Affleck SG Cockerill C Stubberfield R Harris M Page KJ Smith SB Guntrip MC Carter RJ Shaw A Jowett J Stables P Topley ER Wood PS Brignola SH Kadwell BR Reep RJ Mullin KJ Alligood BR Keith RM Crosby DM Murray WB Knight TM Gilmer K Lackey (2001)ArticleTitleThe characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer_Cancer Res_ 61 7196–7203Occurrence Handle1:CAS:528:DC%2BD3MXnsVeht70%3DOccurrence Handle11585755 CASPubMed Google Scholar
DW Rusnak K Lackey K Affleck ER Wood KJ Alligood N Rhodes BR Keith DM Murray WB Knight RJ Mullin TM Gilmer (2001)ArticleTitleThe effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo_Mol Cancer Ther_ 1 85–94Occurrence Handle1:CAS:528:DC%2BD38XlsFSmtbs%3DOccurrence Handle12467226 CASPubMed Google Scholar
D Raben C Bianco B Helfrich E Weng F Ciardiello P Harari (2002)ArticleTitleInterference with EGFR signaling: paradigm for improving radiation response in cancer treatment_Expert Rev Anticancer Ther_ 2 461–471Occurrence Handle1:CAS:528:DC%2BD38Xnt1SqtLc%3DOccurrence Handle12647989 CASPubMed Google Scholar
WJ Slichenmyer DW Fry (2001)ArticleTitleAnticancer therapy targeting the erbB family of receptor tyrosine kinases_Semin Oncol_ 28 67–79Occurrence Handle10.1053/sonc.2001.28557Occurrence Handle1:CAS:528:DC%2BD3MXpt1Wgu7Y%3DOccurrence Handle11706398 ArticleCASPubMed Google Scholar